Drugs / Apatorsen
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00959868 | Jul 2009 → Dec 2012 | urinary bladder cancer | Vancouver Coastal Health | Unknown | No outcome recorded |
| Phase 1 | NCT00487786 | Jun 2007 → Jun 2011 | neoplasm | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT02423590 | Jun 2014 → May 2018 | squamous cell lung carcinoma | Queen Mary University of London | Unknown | No outcome recorded |
| Phase 2 | NCT01844817 | Sep 2013 → Mar 2016 | malignant pancreatic neoplasm | SCRI Development Innovations, LLC | Completed | Missed primary |
| Phase 2 | NCT01829113 | Jul 2013 → Apr 2017 | non-small cell lung carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01780545 | Apr 2013 → Oct 2017 | urinary bladder cancer, urothelial carcinoma | Noah Hahn, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01681433 | Dec 2012 → Jun 2017 | prostate carcinoma | Costantine Albany | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01454089 | Oct 2011 → Nov 2014 | urinary bladder cancer, urothelial neoplasm | Achieve Life Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01120470 | Sep 2010 → Oct 2012 | castration-resistant prostate carcinoma | British Columbia Cancer Agency | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Ionis Pharmaceuticals | Results Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO ionis.com ↗
Phase 1 study of OGX-427 in patients with a variety of cancers. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Ionis Pharmaceuticals | Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO ionis.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apatorsen | “Apatorsen (OGX-427) is a 2'-methoxyethyl-modified antisense oligonucleotide that inhibits Hsp27 expression.” PMID 27022067 ↗ Feb 2016 |
| Known as | OGX-427 | “Apatorsen (OGX-427) is a 2'-methoxyethyl-modified antisense oligonucleotide that inhibits Hsp27 expression.” PMID 27022067 ↗ Feb 2016 |
| Action | Inhibit | “inhibits Hsp27 expression” PMID 27022067 ↗ Feb 2016 |
| Modality | Antisense oligonucleotide | “Apatorsen (OGX-427) is a 2'-methoxyethyl-modified antisense oligonucleotide” PMID 27022067 ↗ Feb 2016 |
| Route | Intravenous | “Apatorsen was administered i.v. weekly in 21-day cycles” PMID 27022067 ↗ Feb 2016 |